Colchicine's anti-inflammatory effect in acute gout is NOT due to inhibiting urate crystal formation or dissolving crystals. Its primary mechanism of action is:
- A Binding to tubulin dimers and preventing their polymerisation, thereby disrupting neutrophil microtubule-dependent migration, degranulation, and phagocytosis of urate crystals ✓
- B Inhibition of xanthine oxidase, reducing uric acid synthesis and crystal precipitation
- C Selective COX-2 inhibition in synovial cells, reducing prostaglandin E2-mediated vascular dilatation
- D Blocking NLRP3 inflammasome activation via adenylyl cyclase stimulation and cAMP increase
Explanation
Colchicine binds to soluble tubulin heterodimers and prevents their polymerisation into microtubules. Since neutrophil chemotaxis, phagocytosis of urate crystals, and degranulation all require intact microtubule dynamics, colchicine effectively halts the cycle of crystal-triggered neutrophil activation and inflammation. It does not inhibit xanthine oxidase (allopurinol/febuxostat do that), does not inhibit COX enzymes (NSAIDs do), and does not directly block the NLRP3 inflammasome (canakinumab/anakinra do that) — though downstream inflammasome activation is reduced as a secondary consequence of impaired crystal phagocytosis.
Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.